TABLE 3

Outcome After Treatment

Patient no.	Initial diagnosis	First PTRT cycle	FAP PTRT cycles (n)	Response* at 6–8 wk after first cycle	Response* at 6–8 wk after third cycle, if applicable	Time to progression since initial PTRT (wk)	Death	Cause of death	Survival since initial FAP PTRT (mo)
1	09/2019	10/2019	2	PD		8	03/2020	PD	5
2	03/2019	10/2019	2	PD		8	06/2020	PD	8
3	09/2019	10/2019	2	PD		8	12/2019	Suicide	2
4	02/2018	10/2019	2	PD		8	02/2020	PD	4
5	01/2019	12/2019	2	PD^†		8	04/2020	PD	4
6	07/2015	10/2019	2	PD		8			Patient alive (05/2021)
7	09/2004	10/2019	2	PD		8	04/2020	PD	6
8	07/2013	10/2019	3	SD	PD	24			Patient alive (05/2021)
9	05/2008	10/2019	2	SD		20			Patient alive (05/2021)
10	03/2015	10/2019	2	PD		8	01/2020	PD	3
11	02/2009	10/2019	1	PD		6	01/2020	Bronchopneumonia	3

*Response was evaluated by RECIST 1.1, on ⁶⁸Ga-FAP-2286 PET/CT (except in patient 5) and tumor marker evaluation after first (in all) and third (in patient 8) PTRT cycles.
↵^†Response was evaluated on RECIST 1.1 and tumor marker evaluation.
FAP = fibroblast activation protein; PTRT = peptide-targeted radionuclide therapy; PD = progressive disease.